

- Losartan (*Cont.*):
 for hypertension, 1624t
 metabolism of, 34t, 35, 42
 for Raynaud's phenomenon, 2164
- Loss of heterozygosity (LOH), 101e-4, 101e-5f, 2305t
- Loss of protective sensation (LOPS), 2407
- Louse-borne diseases
 epidemic typhus. *See* Epidemic (louse-borne) typhus
 relapsing fever. *See* Relapsing fever
- Lovastatin
 adverse effects of, 2199, 2218t, 2447–2448, 2448t
 drug interactions of, 42, 246e-3t, 2447
 for lipoprotein disorders, 2448t
- Low- and middle-income countries
 demographics of
 life expectancy, 93e-1t
 population aged 60+, 93e-2, 93e-2f
 population aged 80+, 93e-2–3, 93e-3t
 population aging indicators, 93e-1t
 health challenges in
 brain drain, 13–14
 burden of disease, 9, 11t, 13e-1–2, 13e-2f, 93e-5, 93e-5f, 93e-5t
 cancer, 16, 16f
 cardiovascular disease, 15–16, 266e-2–3, 266e-2f, 266e-3f
 child mortality, 13e-3, 13e-3f
 diabetes, 15
 health system performance, 13e-3–4, 13e-4f
 HIV/AIDS, 12, 12f, 13f, 1223–1225, 1224f
 life expectancy, 13e-1–2, 13e-2f, 13e-3f
 malaria, 14–15
 skews in research, 13e-4
 social stratification, 13e-4
 tuberculosis, 12–13
 primary care in, **13e-1**
 experiences with, 13e-6–7, 13e-6f
 opportunities to build, 13e-7–8
 revitalization of, 13e-4–6
 smoking patterns in, 266e-4
 travel to
 health problems during, 793–794, 794f
 health problems following, 800–801f, 802, 802t
- Low-density lipoprotein (LDL)
 atherosclerosis and, 291e-5–6
 composition of, 2436–2437, 2436f, 2436t
 elevated levels of. *See also* Lipoprotein disorders
 in metabolic syndrome, 2451, 2453
 pathophysiology of, 2440–2441
 primary (genetic) causes of, 2440t, 2441–2443
 secondary causes of, 2441
 treatment of, 291e-6–7, 291e-8f, 291e-9f, 2453
 estimate of, 2446
 inherited causes of low levels of, 2444–2445. *See also* Abetalipoproteinemia (acanthocytosis)
 in transport of hepatic lipids, 2437, 2437f
- Low-density lipoprotein (LDL) apheresis, 2441, 2449
- Lower esophageal sphincter (LES), 255, 1904, 1905f, 1906
- Lower motor neuron diseases, 2634t, 2636. *See also* Amyotrophic lateral sclerosis (ALS)
- Lower motor neuron pathways, 155f
- Lower motor neuron (neuropathic) weakness, 154, 154t, 157
- Lower urinary tract symptoms (LUTS), 7e-4, 587, 587t
- Low-fat diet, 476
- Low FODMAP diet, 263
- Low-molecular-weight heparin (LMWH), 752
 action of, 750f, 752
 adverse effects of, 753
 assessment of, 407
 discontinuation before lumbar puncture, 443e-1
 dosage of, 752–753
 for DVT/PE treatment, 47, 1635, 1635t
 vs. fondaparinux, 753t
 vs. heparin, 752t
 monitoring treatment with, 752
 for myocardial infarction, 1597, 1598t, 1606
 pharmacology of, 752
 thrombocytopenia induced by. *See* Heparin-induced thrombocytopenia
 for thrombophlebitis, 613
 for VTE prophylaxis, 55, 1637t
- Loxapine, 2722t
- LPL (lipoprotein lipase), 2450
- LPL (lipoprotein lipase) deficiency, 91e-3, 2439–2440, 2440t
- LPS. *See* Lipopolysaccharide (LPS)
- LPS-binding protein, 372e-2
- LPS receptor. *See* CD14 (LPS-receptor)
- LP-X, 2443
- Lrp4 antibodies, 2702
- LRP5 gene mutations, 2489
- LRKK2 gene mutations, 444e-9, 444e-10, 2609, 2613
- LSD (lysergic acid diethylamide), 469e-4
- LTA4H gene, 775
- LTBI (latent tuberculosis infection). *See* Tuberculosis (TB), latent infection
- LTRs (long terminal repeats), 225e-1, 1218–1219, 1219f
- L-type fatty acid binding protein, 1808
- LT- β , 372e-11t
- Lubiprostone
 for constipation, 273, 274
 for irritable bowel syndrome, 1970, 1970t
- Lubricin, 2140, 2226
- Lucio's phenomenon, 829, 1124, 1128
- Ludwig's angina, 233, 236, 1097
- Lues maligna, 1135, 1259
- Lujo virus, 1306t
- Lumbar adhesive arachnoiditis, 117
- Lumbar fracture, 2489
- Lumbar fusion, 120
- Lumbar lordosis, 285
- Lumbar plexus, 2693, 2693f
- Lumbar puncture, **443e-1**
 analgesia for, 443e-1–2
 in coma, 1775
 headache following, 111, 443e-3, 443e-3f, 443e-3t
 imaging and laboratory studies prior to, 443e-1
 in meningitis, 887–888
 needles for, 443e-3, 443e-3f
 in neurologic critical illness, 1779
 normal values, 443e-3t, 443e-4
 patient positioning for, 443e-2, 443e-2f
 in patient receiving anticoagulants or antiplatelet agents, 443e-1
 specimen collection and transport, 150e-4t
 in subarachnoid hemorrhage, 1786
 technique, 443e-2–3, 486e-1v
- Lumbar spinal lesions, 2651
- Lumbar spinal stenosis, 115–116, 116f
- Lumbosacral plexopathies, 462e-19, 2693–2694
- Lumbosacral plexus, 2693, 2694f
- Lumbo virus, 1309t
- Lumefantrine, 246e-2t, 246e-9, 798
- Luminal A breast cancer, 526
- Luminal B breast cancer, 526
- Lumpectomy, 526–528, 531
- Lung
 airways resistance in, 306e-6
 blood flow through, 306e-1
 compliance of, 306e-1–2, 1733
 diffusing capacity of, 306e-6
 elastic recoil pressure of, 306e-1
 flow-related properties of, 306e-2, 306e-2f, 306e-3f, 306e-6
 shunt, 306e-4, 306e-4f
 volume-related properties of, 306e-1–2, 306e-1f, 306e-2f, 306e-6
- Lung abscess, **813**
 anaerobic bacterial, 1098, 1098f
 approach to the patient, 815
 clinical features of, 814
 complications of, 815, 901
 definition of, 813
 diagnosis of, 815
 differential diagnosis of, 815
 epidemiology of, 813–814
 etiology of, 813, 814t, 1098
 hemoptysis in, 245
 pathogenesis of, 814, 814f
 pathology and microbiology of, 814
 prevention of, 815
 prognosis of, 815
 treatment of, 815, 1102
- Lung biopsy
 in granulomatosis with polyangiitis, 386e-1, 386e-5f
 in hypersensitivity pneumonitis, 1683, 1683f
 in interstitial lung diseases, 1710
 in microscopic polyangiitis, 386e-5f
 in vasculitic syndromes, 386e-1
- Lung cancer, **506**
 adenocarcinoma, 507, 507f
 asbestos-related, 1689
 carcinoma of unknown primary and, 120e-2, 120e-2t
 classification of, 507–508, 507f
 clinical features of, 510–511, 510t
 clubbing in, 250
 deaths from, 467t, 468f, 470t, 471t, 506
 diagnosis of, 308e-15–16f, 511–512
 epidemiology of, 506
 genetic considerations in, 101e-2t, 507–509, 507t, 509f
 hemoptysis in, 245–246
 immunohistochemistry of, 508
 incidence of, 467–468, 467t, 468f, 471t, 506
 large cell, 507, 507f
 lymphadenopathy in, 409
 metastatic
 to bone, 119e-4
 clinical features of, 511t
 to CNS, 604f, 604t
 to eye, 206
 to heart, 271e-9f, 271e-9v, 289e-2
 incidence of, 511
 treatment of, 519–521, 520t, 523f
 non-small cell
 metastatic, 519–521, 520t, 523f, 604f
 pathology of, 507–508, 507f
 prognosis of, 516t
 staging of, 512–513, 514f, 516t
 treatment of, 102e-3, 102e-5t, 512, 512f, 515–519, 523f
 occult, 515
 occupational exposures and, 1692–1693
 paraneoplastic syndromes in, 511, 609t, 612t
 pathogenesis of, 508–509
 pathology of, 507–508, 507f
 prevention of, 477
 prognosis of, 516t
 racial/ethnic disparities in treatment of, 16e-1
 radon exposure and, 1693
 risk factors for, 506–507
 screening for, 482, 509–510, 510t
 second malignancies in survivors of, 623
 small cell
 hypokalemia in, 64e-7–8
 immunohistochemistry of, 508
 intestinal pseudoobstruction in, 259–260
 Lambert-Eaton myasthenic syndrome in, 511, 616, 2703
 paraneoplastic syndromes in, 608–609, 609t, 616, 617
 pathology of, 507–508, 507f
 SIADH in, 64e-4–5, 300
 staging of, 513–514
 treatment of, 515f, 522, 522f
 smoking and, 475–476, 506–507, 2730t
 squamous cell, 507, 507f
 staging of, 512–515, 514f, 516t, 1664
 stem cells in, 508
 superior vena cava syndrome in, 510t, 511, 1788, 1789f